Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

velpatasvir

- PMLiVE

Pardes Biosciences, backed by Gilead and Foresite, goes public to advance lead COVID-19 antiviral drug

Pardes’ lead oral antiviral drug candidate is designed to inhibit the main protease of SARS-CoV-2

- PMLiVE

Merck’s appeal to restore hepatitis C patent verdict against Gilead fails

US Supreme Court rejects Merck’s appeal over patent dispute verdict of $2.54bn

- PMLiVE

Gilead gets ‘gold’ in England’s hepatitis C eradication drive

NHS England's tender process drives down cost of medicines

- PMLiVE

NHS England sees off AbbVie’s Hep C legal challenge

Claims of unfair process dismissed by High Court

- PMLiVE

AbbVie sues NHS England over hep C procurement

Accuses NHS of not treating all bidders fairly

- PMLiVE

GSK’s says depot HIV injection works over three years

The injection could rival Gilead’s single-tablet therapy

- PMLiVE

Gilead and Aelix join forces to pursue HIV ‘cure’

The HTI vaccine could replace antiretroviral therapy if it reaches market

Gilead Sciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Biopharma looks to genome editing platform to discover hepatitis B cure

- PMLiVE

The race for a HIV ‘cure’

Supercharging therapies as pharma and patients work together

- PMLiVE

Morning brief: Gilead partners with Verily, Roche expands 4DMT partnership and more

A rapid round up of pharma, biotech and healthcare news

Gilead Sciences

Gilead and Verily team up to map inflammatory diseases

Computational analysis could provide deeper understanding of disease

- PMLiVE

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

AstraZeneca, Roche and Gilead among companies one step closer to approval

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links